Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting Editorial

   


Authors: Yaeger, R.; Solit, D. B.
Title: Overcoming adaptive resistance to KRAS inhibitors through vertical pathway targeting
Abstract: KRAS G12C inhibitors have shown promise in KRAS G12C-mutant lung cancer but intrinsic and acquired resistance are common. Cotreatment with inhibitors of the protein phosphatase SHP2 can abrogate the adaptive response of cancer cells to KRAS inhibitors resulting in greater suppression of MAPK signaling and enhanced tumor growth inhibition. © 2020 American Association for Cancer Research Inc.. All rights reserved.
Keywords: signal transduction; protein expression; unclassified drug; drug efficacy; antineoplastic agent; protein targeting; drug effect; drug resistance; cancer inhibition; drug mechanism; drug response; clinical effectiveness; k ras protein; vemurafenib; human; priority journal; article; amg 510; ars 1620
Journal Title: Clinical Cancer Research
Volume: 26
Issue: 7
ISSN: 1078-0432
Publisher: American Association for Cancer Research  
Date Published: 2020-04-01
Start Page: 1538
End Page: 1540
Language: English
DOI: 10.1158/1078-0432.Ccr-19-4060
PUBMED: 32001483
PROVIDER: scopus
PMCID: PMC7453631
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85082942022&doi=10.1158%2f1078-0432.CCR-19-4060&partnerID=40&md5=369c333714df935a0f76a67ac1320c54
Notes: Article -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. David Solit
    779 Solit
  2. Rona Denit Yaeger
    315 Yaeger
Related MSK Work